

Sjogren's Syndrome

## A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT02701985 2015-004476-30  
BP30037

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants with moderate to severe primary Sjogren's syndrome. The total duration of the study for each participant will be approximately 18 weeks (including screening).

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

**NCT02701985 2015-004476-30 BP30037**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥ 18 Years & ≤ 75 Years

**Healthy Volunteers**  
No